Bradykinin promotes neuron-generating division of neural progenitor cells through ERK activation by Pillat, Micheli Mainardi et al.
RESEARCH ARTICLE
Bradykinin promotes neuron-generating division of neural
progenitor cells through ERK activation
Micheli M. Pillat1, Claudiana Lameu1, Cleber A. Trujillo2, Talita Glaser1, Angélica R. Cappellari3,
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ABSTRACT
During brain development, cells proliferate, migrate and differentiate
in highly accurate patterns. In this context, published results indicate
that bradykinin functions in neural fate determination, favoring
neurogenesis and migration. However, mechanisms underlying
bradykinin function are yet to be explored. Our findings indicate a
previously unidentified role for bradykinin action in inducing neuron-
generating division in vitro and in vivo, given that bradykinin
lengthened the G1-phase of the neural progenitor cells (NPC) cycle
and increased TIS21 (also known as PC3 and BTG2) expression in
hippocampus from newborn mice. This role, triggered by activation of
the kinin-B2 receptor, was conditioned by ERK1/2 activation.
Moreover, immunohistochemistry analysis of hippocampal dentate
gyrus showed that the percentage of Ki67+ cells markedly increased
in bradykinin-treated mice, and ERK1/2 inhibition affected this
neurogenic response. The progress of neurogenesis depended on
sustained ERK phosphorylation and resulted in ERK1/2 translocation
to the nucleus in NPCs and PC12 cells, changing expression of
genes such as Hes1 and Ngn2 (also known as Neurog2). In
agreement with the function of ERK in integrating signaling
pathways, effects of bradykinin in stimulating neurogenesis were
reversed following removal of protein kinase C (PKC)-mediated
sustained phosphorylation.
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INTRODUCTION
During nervous system development, neural stem and progenitor
cells (NPCs) perform the task of proliferating, migrating, and
differentiating in highly accurate patterns. Genetic programs and
specific factors in the microniches control such accuracy. These
factors influence proliferative and neuron-generating cell divisions,
and differentiation programs (Calegari et al., 2005; Lako et al.,
2009; Lukaszewicz et al., 2002). Proliferative division is rapidly
completed, given that it has an abbreviated G1-phase, and generates
two identical precursor cells. By contrast, neuron-generating
division generates two daughter cells, where one or both leave the
cell cycle and undergo differentiation. Recent in vitro and in vivo
studies have demonstrated that NPCs with a longer G1-phase of
the cell cycle perform a neuron-generating division (Calegari et al.,
2005; Calegari and Huttner, 2003; Lako et al., 2009; Lukaszewicz
et al., 2002; Neganova et al., 2009; Orford and Scadden, 2008).
Similarly, expression of the gene TIS21 (also known as PC3 and
BTG2) at the onset of neurogenesis identifies cells switching from
proliferative to neuron-generating division. Expression of this gene,
in the same way as elongation of the G1-phase, serves as a marker
for neuron-generating division (Calegari and Huttner, 2003;
Iacopetti et al., 1999).
NPCs can be obtained from the telencephalon of mice embryos,
and used to reproduce in vitro events of cortical development
in vivo, such as proliferation, migration, neurogenesis and
gliogenesis. As observed in vivo (Tropepe et al., 1999),
fibroblast growth factor-2 (FGF-2) and epidermal growth factor
(EGF) also induce proliferative division of NPCs in vitro,
maintaining cells as multipotent and leading to the formation
of neurospheres (Lukaszewicz et al., 2002; Reynolds and Weiss,
1996). After growth factor removal and cell adhesion,
NPCs differentiate spontaneously (reviewed by Trujillo et al.,
2009).
Distinct dynamics of ERK1 and ERK2 (ERK1/2; also known as
MAPK3 and MAPK1, respectively; hereafter referred to as ERK)
activation are believed to be the underlying cause of differences
in cellular responses, such as proliferation or differentiation, as
described for PC12 cells treated with growth factors (Marshall,
1995; Santos et al., 2007; Sasagawa et al., 2005; Traverse et al.,
1992; Vaudry et al., 2002; von Kriegsheim et al., 2009). For
example, whereas EGF stimulation causes transient ERK activation
in the cytoplasm and results in proliferation, nerve growth factor
(NGF) induces sustained ERK activation and nuclear translocation,
resulting in neuronal differentiation. To achieve the latter sustained
ERK activation, several signaling pathways including those
mediated by phosphoinositide 3-kinase (PI3K), Ras, Ca2+, protein
kinase C (PKC) and cAMP might be required. Once attained,
sustained ERK activation followed by nuclear translocation is
sufficient for induction of neurogenesis.
Recent studies have demonstrated a new role of bradykinin in
promoting cell migration and neurogenesis during in vitro
differentiation of pluripotent cells and embryonic NPCs (Martins
et al., 2005; Pillat et al., 2015; Trujillo et al., 2012). The opposite
occurs in NPCs treated with the kinin-B2 receptor (B2BkR, also
known as BDKRB2) antagonist HOE-140 and also in NPCs from
embryos of B2BkR−/− mice, i.e. decreased cell migration and
neurogenesis. B2BkR−/− mice have decreased neuronal marker
expression in several stages of development, suggesting the
involvement of bradykinin in neuronal phenotype determination
in vivo (Trujillo et al., 2012). However, the mechanisms triggered by
bradykinin to coordinate migration, proliferation and neuronalReceived 3 June 2016; Accepted 27 July 2016
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differentiation remain unknown. Here, we provide mechanisms for
neuron-generating divisions in NPCs and in hippocampus from
newborn mice, and delineate the intracellular signaling pathways
that might serve as key determinants of bradykinin-induced effects
in the cell cycle followed by neuronal differentiation.
RESULTS
Bradykinin-mediated effects on the proliferation and cell
cycle of undifferentiated NPCs – the cell cycle length
predicts cell fate
EGF and FGF-2 induce proliferative division of NPCs, keeping
them in their undifferentiated state (Lukaszewicz et al., 2002;
Reynolds and Weiss, 1992, 1996). In this context, we evaluated the
effect of bradykinin on proliferation of undifferentiated cells
stimulated by growth factors. EGF and FGF-2 (both at 20 ng/ml
final concentrations) were added to the culture medium 1 h prior to
bradykinin (1 μM) treatment and cells were analyzed after 24 h in
this medium (Fig. 1A,B). The presence of bradykinin resulted in a
significant reduction in proliferation in comparison with samples
treated with growth factors only, as observed by their significantly
lower BrdU incorporation after 2 h of treatment (P=0.0126). We
sought to identify in which phase of the cell cycle NPCs stimulated
with bradykinin in the presence of growth factors are primarily
found. For this purpose, cells were double-labeled for BrdU (after
30 min of treatment) plus propidium iodide (Fig. 1C) and Ki67 plus
propidium iodide (Fig. 1D). The addition of bradykinin to cells
pretreated with growth factors resulted in an accumulation of cells in
G1-phase, compared to samples treated only with growth factors
(Fig. 1E; P=0.0217).
It is important to stress that NPCs undergoing neuron-generating
division have a longer G1-phase than those performing proliferative
division (which have an abbreviated G1 phase) (Calegari et al.,
2005; Orford and Scadden, 2008). Thus, given that the cell cycle
length predicts cell fate, we assessed whether this neuron-generating
ability in response to bradykinin signaling was accompanied by an
increase in the length of the G1-phase of the cell cycle. For this
purpose two strategies were used for analysis, which are briefly
described in the Materials and Methods section (Lukaszewicz et al.,
2002; Nowakowski et al., 1989; Storey, 1989; Wilcock et al., 2007).
Cell cycle and G1-phase lengths of NPCs exposed to the growth
factors EGF and FGF-2 and bradykinin were markedly increased
compared to cell cycle and G1-phase length of NPCs exposed to
growth factors alone (Table 1), as revealed by flow cytometry
experiments. These data demonstrate that proliferating NPCs in the
presence of bradykinin adopted a slower cell cycle progression
(longer G1-phase), which is characteristic for cells that generate
neurons.
Signaling pathways activated by bradykinin in NPCs
For delineating intracellular signaling pathways that might serve as
key determinants of bradykinin-induced effects in cell cycle
followed by neuronal differentiation in NPCs, we examined the
activities of various intracellular signaling pathways. A significant
increase in intracellular cAMP concentration ([cAMP]i) was
observed after 1 and 2 min of exposure to bradykinin with a
subsequent decay to baseline (Fig. 2A; P=0.012). The B2BkR can
also catalyze the exchange of GTP for GDP on the α subunits of Gi
and Gs proteins (Blaukat et al., 2000; Hall et al., 1993; Hanke et al.,
2006; Liebmann et al., 1996, 1990), even though it has been often
described as a prototypical Gq-protein-coupled receptor. Thus, we
assessed if the B2BkR could also be coupled to any member of
the Gs or Gi protein family in NPCs or if the Gq protein and its
downstream pathway could affect bradykinin-stimulated cAMP
production. Cells were treated with cholera toxin (0.5 μg/ml; 16 h) to
activate all Gs proteins, with the Gq protein inhibitor
YM254890 (10 μM; 15 min), with the PLC-β inhibitor U73122
(10 μM; 30 min), or with the Gi protein inhibitor pertussis toxin
(200 ng/ml; 16 h). Samples were then stimulated or not for 2 min
with bradykinin (1 μM), and changes in [cAMP]i levels were
determined. Pre-treatment with only pertussis toxin prevented the
bradykinin-stimulated [cAMP]i increase (Fig. 2B). In this context, it
is known that βγ subunits of the Gi protein can activate adenylate
cyclase II, IV and VII, and that βγ subunits are sensitive to pertussis
toxin (Chen et al., 1995). Therefore, our data suggest that the B2BkR
is also coupled to Gi proteins in NPCs, and that their βγ subunits
might induce activation of adenylate cyclase and cAMP production.
Previous studies have shown that bradykinin induces an elevation
in the concentration of intracellular free Ca2+ ([Ca2+]i) by activating
B2BkR in four models of neural differentiation (Appell and
Barefoot, 1989; Martins et al., 2008, 2005; Nascimento et al.,
2015; Trujillo et al., 2012). Thus, we aimed to find the intracellular
signaling pathways that mediate the bradykinin-induced [Ca2+]i
increase. For this purpose, NPCs were pre-treated with YM254890,
pertussis toxin, or YM254890 plus pertussis toxin. Surprisingly,
treatments with YM254890 or pertussis toxin only partially inhibited
the response of NPCs to bradykinin from 5.27±0.49 to 3.28±0.39
(37.7% of suppression) or 3.73±0.12 (29.2% of suppression),
respectively (mean±s.e.m.; Fig. 2C,D). By contrast, simultaneous
inhibition of both Gq and Gi proteins (YM254890 plus pertussis
Fig. 1. Effects of bradykinin on proliferation and cell cycle of NPCs.
(A) Growth factors (GFs; EGF plus FGF2; both at 20 ng/ml), combined or not
with bradykinin (BK; 1 μM), were included in the culture medium of NPCs for
24 h, and 50 μM BrdU was added for the last 2 h of culture. Cumulative BrdU
labeling was detected with Alexa Fluor (AF) 488 staining and quantified by flow
cytometry. (B) Mean±s.e.m. percentages of proliferating cells (BrdU+ cells)
(n=6 independent experiments). (C) Representative dot-plots showing the
number of cells in each phase of the cell cycle in NPCs treated with growth
factors or growth factors and bradykinin. After a short pulse with BrdU (50 μM;
30 min), only cells in S-phase are labeled with anti-BrdU Alexa Fluor 488.
(D) Representative dot-plots for Ki67 and propidium iodide fluorescence
staining of undifferentiated cells treated with growth factors in the absence or
presence of bradykinin. (E) Mean±s.e.m. percentage of the proportion of
NPCs in each phase of the cell cycle (n=4 independent experiments). *P<0.05
(two-way ANOVA with a Bonferroni post hoc test).
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toxin) blocked the bradykinin-induced [Ca2+]i increase (0.33±0.19;
93.7% of suppression), suggesting that both types of G proteins are
involved in B2BkR-mediated responses, and that co-activation of Gq
and Gi proteins exerts synergistic effects on bradykinin-induced
[Ca2+]i increases (P=0.0005), such as observed in experiments
conducted with platelets (Shah et al., 1999). Subsequently, we
provided evidence that the bradykinin-induced [Ca2+]i increase
occurs by mobilization of intracellular Ca2+ stores. Pre-treatment of
NPCs for 1 h with thapsigargin, an inhibitor of the sarco- and
endoplasmic reticulum Ca2+ ATPase (SERCA), completely blocked
bradykinin-induced [Ca2+]i increases (Fig. 2C,D; P=0.0002).
To determine which other signaling pathways might serve as key
determinant of bradykinin effects in neural differentiation of NPCs,
intracellular signal-transducing kinase activities were examined. For
this, cells initially starved for 6 h were stimulated or not for 10 min
with bradykinin (1 μM), followed by detection of phosphorylated
(p)-STAT3, JNK family proteins (p-JNK), Akt family proteins
(p-Akt) and p38 MAPK family proteins (p-p38) by flow cytometry
(Fig. 2E,F). Bradykinin-treated samples did not show any
significant differences in levels of phosphorylated JNK and
STAT3, compared to untreated samples. In contrast, higher levels
of p-p38 (P=0.0446) and p-Akt (P=0.0071) were observed after
Table 1. Cell cycle distributions of NPCs treated with growth factors, and growth factors plus bradykinin
Analysis
Cell cycle length (h)
Proliferation
fraction (%)
Complete
cycle S-phase
G1+ G2/M
phase
G2/M
phase G1 phase
Growth factors A 11.41±0.72 2.50±0.24 8.9±0.62 2.16±0.42 6.74±0.62 73.95±5.16
B 10.08±0.81 2.96±0.32 – 2.16±0.52 4.96±0.81 –
Growth factors+
bradykinin
A 17.30±0.95* 2.40±0.37 14.9±0.84 2.20±0.31 12.70±0.79* 75.50±8.75
B 18.00±1.21* 3.20±0.53 – 2.16±0.22 12.64±0.88* –
The length of each stage of the cell cycle times in hours are derived from cumulative BrdU labeling experiments and two different analysismethods, denoted A and
B, as described in the Materials and Methods section. Growth factors (EGF plus FGF2; both at 20 ng/ml), combined or not with bradykinin (1 μM), were added to
the culture medium of NPCs for 24 h, and 50 μMBrdUwas added for the last 30 min or 2 h of culture (n=4 independent experiments). Data from flow cytometry are
shown as mean±s.e.m. percentages for the whole population. *P<0.05 (two-way ANOVA with a Bonferroni post hoc test).
Fig. 2. Bradykinin-induced changes in [cAMP]i, [Ca
2+]i and phosphorylation cascades in NPCs. (A) Kinetics of cAMP formation following stimulation with
bradykinin (BK, 1 μM; n=4). (B) Pre-incubation with cholera toxin (CT; 0.5 μg/ml), YM254890 (YM; 10 μM), U73122 (U73; 10 μM), pertussis toxin (PT; 200 ng/ml)
before bradykinin (1 μM) stimulus and [cAMP]i determination (mean±s.e.m.; n=4). (C) Effects of pre-treatments with pertussis toxin, YM254890 and
thapsigargin (Thapsi; 1 μM) on bradykinin-induced [Ca2+]i transient elevation in undifferentiated neurospheres. (D) Mean±s.e.m. values of Δ[Ca
2+]i (n=4).
(E) Representative flow cytometry histograms show staining with antibodies against the indicated phosphorylated enzyme conjugated to Alexa Fluor (AF) 488 in
6-h-starved NPCs stimulated with bradykinin (10 min). (F) Mean±s.e.m. expression levels of these phosphorylated enzymes were estimated by determining the
mean fluorescence intensity (MFI) for each sample (n=6). (G) Wild-type (WT; n=6) and B2BkR−/− NPCs (n=1) were stimulated with bradykinin in the
absence or presence of the U0126 (10 μM), PD98059 (PD; 20 μM) or PMA (50 ng/ml). NPCswere then stainedwith anti-p-ERK antibodies (AF 488) and analyzed
by flow cytometry. (H) Data shown as mean±s.e.m. of p-ERK expression levels estimated by MFI. CTL, control. *P<0.05, **P<0.01, *** P<0.001 (Student’s t-test
and two-way ANOVA with a Bonferroni post hoc test).
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bradykinin stimulation. It is known that several signaling pathways,
such as the PI3K–Akt, PKC, Ca2+, p38 MAPK and cAMP, can
regulate ERK activation or integrate their signals in this signaling
cascade (Blaukat et al., 2000; Bouschet et al., 2003; Murray, 1998;
Westermarck et al., 2001). Based on this fact and known effects of
ERK in controlling processes such as proliferation and neuronal
differentiation, the influence of bradykinin on this MAPK was
further studied (Fig. 2G,H). Phorbol 12-myristate 13-acetate (PMA)
and inhibitors of MEK–ERK pathway U0126 and PD98059 were
used as positive and negative controls, respectively, for ERK
phosphorylation. Bradykinin increased the level of p-ERK
expression when compared to control samples in neurospheres
from wild-type (WT) mice (P=0.0001). PMA induced ERK
phosphorylation, whereas bradykinin did not provoke any effect
on ERK phosphorylation in neurospheres from B2BkR-knockout
mice, confirming that bradykinin exerts its effects specifically
through B2BkR stimulation.
The activation and regulation of ERK by one or more pathways
result in distinct kinetics and cell localization, which in turn cause
different cell responses. Namely, in PC12 cells, ERK induces either
proliferation when activated transiently, or induces neuronal
differentiation and suppression of proliferation when it remains
activated for a prolonged time and translocates to the nucleus (Impey
et al., 1999; Marshall, 1995; Santos et al., 2007; Sasagawa et al.,
2005; Traverse et al., 1992; von Kriegsheim et al., 2009). In order to
assess how long ERK activity is sustained, untreated NPCs (control)
and NPCs treated with bradykinin (1 μM) for 2, 5, 10, 15, 30 and
60 min were analyzed by flow cytometry using an anti-p-ERK
antibody. Bradykinin activated ERK for at least 60 min (Fig. 3A,B).
NPCs starved for 6 h were kept for 15 min in the absence or presence
of bradykinin (1 μM), fixed, and stained for p-ERK and the
cytoplasmatic protein nestin. As observed in the representative
images and bar plots (Fig. 3C,D), the proportion of cells expressing
detectable levels of p-ERK in the nucleus increased significantly in
bradykinin-treated samples compared to controls (P=0.0187). In
agreement with results obtained in NPCs, bradykinin treatment
induced a sustained ERK activation in PC12 cells, as revealed by
flow cytometry experiments (Fig. 3A,B). Sublocalizations of ERK
after bradykinin stimulation in PC12 cells starved for 6 h were
further studied by using a protocol to separate nuclear and
cytoplasmic protein extracts followed by western blotting assays.
Increased p-ERK amounts in the nuclear extract fraction after
bradykinin stimulation were observed, when compared to
untreated cells (Fig. 3E,F; P=0.0336). No significant differences
were observed in the ratio between p-ERK and total ERK
concentrations in the cytoplasmic extract. NGF stimulation
(positive control), as expected, resulted in an increase of p-ERK
levels in the nucleus. In Fig. 3E, controls of separation efficiency
confirmed the nuclear and cytoplasmic localization of histone H1
and β-actin protein, respectively.
Fig. 3. ERK phosphorylation profiles upon bradykinin (BK) stimulation of NPCs and PC12 cells. (A) Kinetics of ERK phosphorylation (p-ERK) upon
treatment of NPCs and PC12 cells with bradykinin (BK, 1 µM). Cells were unstimulated cells or stimulated with bradykinin for 5, 10, 15, 30 and 60 min or for 10 min
with PMA (50 ng/ml). (B) Kinetics of p-ERK activation (mean±s.e.m. from mean fluorescence intensity, MFI) after bradykinin addition (n=5). (C) Nuclear or
cytoplasmic distribution of p-ERK in NPCs stimulated for 15 min with bradykinin (viewed at a 200× magnification). (D) Bradykinin augmented the proportion of
cells expressing detectable levels of p-ERK in the nucleus, but did not alter levels of this enzyme in the cytoplasm (mean±s.e.m., n=4). (E) PC12 cells were
stimulated or not with bradykinin for 15 min and nuclear (N) and cytosolic (C) fractions were blotted with anti-p-ERK, anti-ERK, anti-β-actin and anti-histone H1
antibodies. Control reactions with β-actin and histone H1 immunodetection show the efficiency of cytosolic and nuclear preparations, respectively. (F) Bradykinin
treatment augmented the presence of p-ERK in the nucleus (mean±s.e.m., n=6). *P<0.05 (two-way ANOVA with a Bonferroni post hoc test).
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Signaling pathways activated by bradykinin that modulate
migration and proliferation of NPCs
As already published in earlier studies of our group, bradykinin
treatment favors neural migration after differentiation of mouse and
rat NPCs (Pillat et al., 2015; Trujillo et al., 2012). Neural cells
present a radial migration pattern from the edge of neurospheres and
the region limited by dotted lines comprised ∼95% of migrating
cells. Here, we evaluated the dose–response curve of bradykinin
(1 nM, 10 nM, 0.1 μM, 1 μM and 10 μM), and the involvement of
PI3K–Akt, ERK and p38 MAPK pathways in bradykinin-induced
neural migration. None of the pharmacological inhibitors of ERK
(PD98059 20 μM; 10 μM U0126), p38 (10 μM SB203580) and
PI3K–Akt (20 μM Ly294002) had any effect on cell viability
(Fig. S1) and Akt activation by bradykinin occurred through PI3K,
but ERK activation did not involve PI3K stimulation (Fig. S1).
Although a dose of 0.1 µM of bradykinin promoted migration,
because 1 µM had the maximum effect on neural migration, we used
this concentration in the subsequent assay (Fig. 4A; Fig. S2). Pre-
treatments with PD98059, U0126 and Ly294002 did not prevent the
increase in bradykinin-induced migration. Nevertheless, inhibition
of p38 MAPK by SB203580 resulted in a substantially lower
number of migrating cells, and bradykinin had no effect on
migration when p38 MAPK was inhibited. Cells were also treated
with SB203580 plus EGF (20 ng/ml) as a positive control of the
experiment. Taken together, these data suggest that bradykinin-
induced cell migration during differentiation depends on p38
MAPK activation, but does not depend on the ERK and PI3K–Akt
pathways.
Signaling pathways triggered by bradykinin that involved
suppression of proliferative division stimulated by growth factors
(FGF2 plus EGF) were investigated, by using the strategy of Dixon
et al. (2002). Briefly, neurospheres were pre-treated for 30 min
with EGF and FGF2 (20 ng/ml each) and then treated for 30 min
with ERK (PD98059 and U0126), p38 (SB203580) and PI3K
(Ly294002) inhibitors. Finally, bradykinin (1 μM) was maintained
for 24 h in the culture medium. The pharmacological inhibition of
ERK and p38 routes completely blocked the effect of bradykinin on
suppressing growth-factor-stimulated proliferation, as shown with
propidum iodide staining and quantified by flow cytometry
(Fig. 4B). These results suggest that bradykinin suppressed the
proliferative division of NPCs through activation of MAPKs (ERK
and p38) cascades, but did not depend on the PI3K–Akt pathway
(P=0.0487).
Bradykinin-activated signaling pathways for NPC fate
determination
It is known that bradykinin treatment results in an increase of β3-
tubulin and a decrease of GFAP-positive cells (Martins et al.,
2008; Pillat et al., 2015; Trujillo et al., 2012). Here, we
determined expression levels of further neural markers using
flow cytometry techniques (Fig. 5A,B) and qualitative
immunofluorescence studies (Fig. 5C,D), and investigated
bradykinin-activated signaling pathways that function in
fostering NPC neurogenesis. Chronic treatment with 1 µM
bradykinin throughout the course of differentiation decreased
the frequency of S100β-positive cells (a glial-cell-specific protein,
in agreement with a previous work of our group, Trujillo et al.,
2012), whereas the frequency of MAP2-positive cells (neuron-
specific protein) was significantly increased (Fig. 5A,B). These
effects were confirmed by microscopic analysis of immunostained
cells (Fig. 5C,D). Now, we show, by flow cytometry analysis, that
bradykinin completely lost its effect to promote neurogenesis
when ERK signaling was blocked by the presence of 20 μM
PD98059 or 10 μM U0126 (Fig. 5E). Furthermore, under these
conditions gliogenesis was promoted and neurogenesis reduced
compared to the untreated control differentiation (Fig. 5E), such
as observed in experiments conducted in the presence of B2BkR
antagonists (Trujillo et al., 2012). The importance of ERK in the
mechanisms of neurogenesis imposed by bradykinin was
confirmed by microscopic analysis of immunostained cells
(Fig. 5F,G).
In this context, it is well known that Hes1 is a repressor-type
basic helix-loop-helix (bHLH) gene in neurogenesis, given that it
inhibits neurogenic bHLH transcription factors, such as MASH1
(also known as Ascl1) and Ngn2 (neurogenin 2, also known as
Neurog2) (Kageyama et al., 2008). Thus, it is important to stress
that Hes1 inactivation leads to acceleration of neurogenesis
(Imayoshi et al., 2008). Expression of Hes1 mRNA was
downregulated in NPCs in response to bradykinin stimulation
(Fig. 5I). Interestingly, we found that bradykinin completely lost its
effect on Hes1 expression under conditions of ERK inhibition.
Moreover, expression of the neurogenic factor Ngn2 was
significantly upregulated in response to bradykinin treatment,
whereas pre-treatment with U0126 prevented this bradykinin-
promoted effect (Fig. 5I). Taken together, these results confirm the
importance of ERK in the mechanisms of neurogenesis imposed by
bradykinin.
A further question was whether bradykinin exerts its effects in
modulating differentiation through the PI3K–Akt or p38 MAPK
pathways. Immunofluorescence and flow cytometry data shown in
Fig. 5E and H, respectively, revealed that, even when PI3K–Akt is
inhibited, bradykinin induced an increase in the percentage of cells
expressing β3-tubulin and a decrease in the percentage of cells
Fig. 4. Effects of bradykinin-induced signaling on migration and growth-
factor-stimulated proliferative division. (A) Migration after 7 days of neural
differentiation in the absence or presence of bradykinin (BK; 1 nM, 10 nM,
0.1 μM, 1 μM or 10 μM), U0126 (10 μM) and PD98059 (20 μM), SB203580
(10 μM), Ly294002 (30 μM) or EGF (20 ng/ml). Cells were treated with the
inhibitors 1 h before bradykinin (1 μM) addition. Neural migration from the edge
of neurospheres is calculated as the mean±s.e.m. percentage of basal
migration. *P<0.05, **P<0.01, #P<0.05 versus control inhibitor, ##P<0.01 versus
control inhibitor (two-way ANOVAwith a Bonferroni post hoc test). (B) NPC
proliferation was assessed by flow cytometry analysis of propidium iodide
staining. GFs, growth factors (20 ng/ml EGF, 20 ng/ml FGF2). Values are
expressed as mean±s.e.m. of proliferating cells (cells in S+G2/M-phase), n=5.
*P<0.05 versusgrowth factors (two-wayANOVAwith aBonferroni post hoc test).
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expressing GFAP at the end of differentiation (day 7). These data
suggest that bradykinin acts on NPC differentiation independently
from the PI3K–Akt pathway. Inhibition of p38 MAPK in the
presence of bradykinin increased the population of cells expressing
β3-tubulin and reduced the percentage expressing GFAP in
comparison to control experiments (Fig. 5E,H). Thus, SB203580
plus bradykinin treatment resulted in similar effects to those
observed in bradykinin-treated samples during differentiation.
These data suggest that bradykinin acts in modulating NPC
differentiation independently from the p38 pathway.
Fig. 5. Effects of bradykinin-induced signaling on differentiation of mouse NPCs. (A) Representative flow cytometry histograms comparing frequencies of
cells expressing S100β and MAP2 in mouse NPCs differentiated for 7 days in the absence (control; solid gray histogram) or presence of 1 μM bradykinin (BK,
black dotted line). Both secondary antibodies were conjugated to Alexa Fluor (AF) 488. (B) Mean±s.e.m. of percentage of S100β+ (in agreement with a previous
work of our group, Trujillo et al., 2012) andMAP2+ cells. Qualitative immunostaining shows differences in S100β+ (green) and β3-tubulin+ (red) cells (C) or MAP2+
(green) cells (D) between control and 1 μM bradykinin-treated neurospheres during differentiation. DAPI-labeled nuclei were used for cell counting.
(E) Neurospheres were differentiated in the presence or absence of U0126 (10 μM), PD98059 (PD, 20 μM), Ly294002 (Ly, 20 μM) or SB203580 (SB; 10 μM).
Cells were treated with the inhibitors 1 h before bradykinin (1 μM) addition. Flow cytometry data for GFAP (AF 488) versus nestin (AF 555), and MAP2 (AF 488)
versus β3-tubulin (AF 555) expression in differentiated neurospheres were obtained in the absence or presence of treatments described above. Data are
presented asmean±s.e.m. percentages of glial cells (GFAP+ nestin−) or neurons (MAP2+ β3-tubulin+). (F,G,H) Neurospheres were treated, fixed and stained with
anti-β3-tubulin (AF 555; red) and anti-GFAP (AF 488; green) antibodies. (I) Hes1, Ngn2 and MASH1 gene expression levels in the absence or presence of
bradykinin and/or U0126. Data are representatives of at least three independent experiments and shown as mean±s.e.m. *P<0.05, ***P<0.001 (Student’s t-test
and two-way ANOVA with a Bonferroni post hoc test). Scale bars: 10 μm.
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Rewiring ERK dynamics redirects phenotypic response to
bradykinin
Given that in molecular mechanistic investigations of neurogenesis,
PC12 cells provide a broad basis for comparison with previous
studies, we also made use of this model in this study. We initially
investigated the differentiation of non-treated (control, CTL),
NGF-treated (50 ng/ml) or bradykinin-treated (1 μM) PC12 cells
on an adherent matrix of poly-L-lysine and laminin for 48 h. NGF
induced differentiation as expected, and bradykinin also enhanced
differentiation because we observed a significant increase in the
number of cells with more than three neurites (P=0.0334) and a
reduction in the percentage of cells without neurites (P=0.0280)
(Fig. 6A,B). As already mentioned, transient and sustained ERK
activation regulates cell fates, such as growth and differentiation, in
PC12 cells (Marshall, 1995; Santos et al., 2007; Traverse et al.,
1992; Vaudry et al., 2002). Here, we performed the same kinetic
experiments of ERK stimulation by EGF and NGF, which induce
transient and sustained ERK activation, respectively (Fig. 6C,D).
Additionally, it has been demonstrated that sustained ERK
activation occurs by stimulation of two or more pathways that
integrate activating this MAPK. Thus, the initial transient and the
subsequent sustained phase can be disrupted (York et al., 1998). In
view of that, we modulated the kinetics of ERK activation by
bradykinin in order to evaluate the importance of sustained ERK
activation in neurogenesis induction. For this, classical PKCs
(cPKCs; activated by Ca2+, diacylglycerol and phosphatidylserine)
Fig. 6. Rewiring ERKdynamics redirects phenotypic response to bradykinin. (A) Representative images of neural differentiation of PC12 cells followingNGF
(50 ng/ml), bradykinin (BK, 1 μM) and Gö6973 (Gö; 10 μM) treatment for 48 h captured by differential interference contrast (DIC) microscopy. Scale bar: 10 μm.
(B) Mean±s.e.m. percentages of undifferentiated (without neurites) or differentiated cells (with three or more neurites) after indicated treatment. Histograms
and quantification of time-dependent ERK activity profiles upon stimulation with NGF or EGF (C,D), BK and Gö+BK (E,F) in PC12 cells, and BK and Gö+BK
in NPCs (G,H), obtained by flow cytometry analysis. Data are shown asmean±s.e.m. of p-ERK-immunostaining (n=4). *P<0.05, **P<0.01 versus control, #P<0.05
versus bradykinin (two-way ANOVA with a Bonferroni post hoc test).
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were inactivated by using the inhibitor Gö6973 (Gö; 10 μM; 1 h).
Fig. 6E,F shows that pre-treatment with Gö blocked sustained ERK
activation stimulated by bradykinin. In other words, bradykinin
started to activate ERK only transiently, similar to effects of EGF
stimulation. Additionally, pre-treatment with Gö (Fig. 6G,H) and
thapsigargin (1 μM for1 h; Fig. S1F,G) significantly decreased
sustained ERK activation stimulated by bradykinin in NPCs. We
can conclude, in advance, that ERK is activated by the integration of
two or more pathways (including Ca2+ and cPKCs) upon
stimulation with bradykinin in NPCs and PC12 cells. Thus, it is
possible that the activation of ERK, regardless of Ca2+ and/or cPKC,
comes from the cAMP (Bouschet et al., 2003) and/or Ras (Blaukat
et al., 2000) and/or β-arrestin pathway (Khoury et al., 2014). In this
context, it is known that some these pathways synergistically
activate ERK. Moreover, each of them is individually necessary for
attaining the profile of sustained ERK activation in PC12 cells
(Bouschet et al., 2003; von Kriegsheim et al., 2009). Therefore,
given that cPKC was necessary to attain the sustained ERK
activation, i.e. the pre-treatment with Gö removed sustained ERK
activation by bradykinin, we evaluated its effect on neuronal
differentiation. The pre-treatment with this inhibitor reversed the
bradykinin effect on neuritogenesis (Fig. 6A,B; cells with more than
three neurites, P=0.0396, versus bradykinin and cells without
neurites, P=0.0306 versus bradykinin), suggesting that sustained
ERK activation might be a mechanism of inducing neurogenesis by
bradykinin.
Fig. 7. Effect of bradykinin on
neurogenesis in vivo. The ventricles
of newbornmice (P0–P1)were injected
with vehicle, bradykinin (BK, 1 µM),
HOE-140 (1 µM) or U0126 (10 µM).
After 1 week, P7–P8 mice were deeply
anesthetized and the brains were
dissected carefully. (A) Sections were
triply labeled for MAP2 (green) and
Ki67 (red) and NeuN (lilac)
immunofluorescences. Scale bar:
100 µm. (B) Quantification of Ki67+
cells in the neurogenic zone of the
hippocampal dentate gyrus (white lines
in A show ROIs). The number of
animals was four in each group. Data
are shown as mean±s.e.m.
(C) Representative merged channels
showing a ROI analyzed by tissue
cytometry using the StrataQuest™
software. (D) Quantitative in situ
analysis of Ki-67+ nuclei in the
neurogenic zone by tissue cytometry.
DAPI was used as master channel to
identify all nuclei in the ROI. For each
nucleus the DAPI area (i.e. nuclear
size, x-axis) and the relative
fluorescence intensity as the ‘70%
percentile’ (i.e. themean intensity of the
30% of brightest pixels in the Ki67
channel per nucleus) were measured.
The cut-off for the x-axis was set to 10
μm in order to distinguish between
prominent nuclei as well as small nuclei
and potential segmentation artifacts.
The cut-off for the y-axis was set to 70
as only strong red signals were
accepted as clearly Ki67+. Thus, the
number of Ki67+ cells in the neurogenic
zone of each sample appears in the
upper right quadrant of each dot plot.
(E) Quantification of Ki67+ cells in ROI
with the StrataQuest software.
Data are shown as mean±s.e.m.
(F) Quantification by real-time PCR of
TIS27mRNA expression (fold change
compared tocontrol) in cell lysates from
hippocampus after 24 h of treatment
with bradykinin, HOE-140 or U0126
and bradykinin (n=4 animals in each
group, the experiments were
conducted in triplicate). *P<0.05,
***P<0.001 (two-way ANOVAwith a
Bonferroni post hoc test).
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Influence of the bradykinin signaling on hippocampal
neurogenesis
Finally, we investigated whether bradykinin and the ERK pathway
affect cell division and neurogenesis in vivo. To assess this
question, we injected (1 µl) vehicle, bradykinin (1 µM), HOE-140
(1 µM) or U0126 (10 µM) into the ventricles of newborn mice
[postnatal day (P)0–P1]. After 1 week, mice (P7–P8) were deeply
anesthetized and brains were dissected carefully. Sections were
labeled for MAP2 (green), Ki67 (red), DCX (doublecortin; red),
and NeuN (lilac) (Fig. 7A; Fig. S3A). It is important to stress that
analysis of the proliferation rate in the neurogenic zone of the
hippocampal dentate gyrus [region of interest (ROI) shown in
Fig. 7A] is relevant, because this zone is composed of quiescent
stem cells, and the proliferation of these cells is the first step in
the process of neurogenesis (Orford and Scadden, 2008).
For better characterization of the influence of bradykinin
signaling on neurogenesis in vivo, proliferating cells (Ki67+
cells) within ROIs were quantified by two methods, (1) standard
immunohistochemistry analysis counting Ki67+ cells (Fig. 7B)
and (2) automatic analysis of these cells by StrataQuest software
(Fig. 7C–E). Fig. 7C shows merged channels and ROI analyzed by
this software, whereas Fig. 7D presents representative dot-plots of
nuclear size versus relative fluorescence intensity of Ki67. Both
types of analysis revealed that the presence of Ki67+ cells in the
ROI was markedly increased in bradykinin-treated mice compared
with those treated with vehicle or HOE-140 (Fig. 7B,E).
Furthermore, under these conditions, bradykinin significantly
lost its effect when ERK signaling was blocked by the presence of
10 μM U0126, as determined by StrataQuest software analysis
(Fig. 7E).
The neurogenic effect of bradykinin and the importance of ERK
in the mechanisms imposed by this kinin in vivowere also analyzed
by microscopic analysis of DCX (a neurogenic marker) expression
levels in neurogenic zone of the hippocampal dentate gyrus,
estimated by mean fluorescence intensity (MFI) in ROIs (Fig. S3).
In fact, levels of DCX were upregulated in response to bradykinin,
and pre-treatment with U0126 prevented this bradykinin effect.
Under the same conditions, we also evaluated the expression of
the TIS21mRNA in hippocampus of P1–P2 mice by real-time PCR,
given that this gene is specifically expressed in stem cells that, at
their next division, will generate postmitotic neurons, but not in
proliferating stem cells (Iacopetti et al., 1999). Expression of the
TIS21 mRNA in the stem cells occurs specifically during G1-phase
of neuron-generating divisions (Calegari and Huttner, 2003;
Iacopetti et al., 1999). We observed that TIS21 mRNA was
markedly increased in bradykinin-treated mice (P=0.0225; Fig. 7F;
216% of control signal). Importantly, the responses of HOE-140
and U0126 plus bradykinin-treated mice were significantly lower
than those of the vehicle-treated mice (P=0.0001 and P=0.0006,
respectively; ∼30% of control signal). In other words, bradykinin-
induced TIS21 expression required the ERK signaling pathway.
Taken together, these data demonstrate that bradykinin induces
neuron-generating divisions in vivo and suggest that ERK is
involved in effector mechanisms of neurogenesis triggered by
bradykinin.
DISCUSSION
Here, we studied the underlying mechanisms of bradykinin-induced
neurogenesis. Among the main findings, we highlight the influence
of bradykinin on division of undifferentiated NPCs. The change of
type of cell division mediated by this kinin is dependent on ERK
activity, as is shown by elongation of G1-phase of NPCs cycle
in vitro and TIS21 expression in vivo, characteristics of neuron-
generating division (Calegari and Huttner, 2003; Iacopetti et al.,
1999; Neganova et al., 2009). Bradykinin evokes sustained ERK
activation with its concomitant translocation to the nucleus in NPCs
and PC12 cells. This type of dynamics of ERK activation is well
known for resulting in neurogenesis of PC12 cells (Marshall, 1995;
Sasagawa et al., 2005; Traverse et al., 1992; Vaudry et al., 2002).
The results presented in this study, including the modulation of
ERK kinetics, followed by the redirection of phenotype induced by
bradykinin, suggest that the sustained ERK activation and
translocation to the nucleus is the mechanism of bradykinin action
in fostering neurogenesis. Moreover, ERK inhibition blocked the
bradykinin effect in downregulating expression of Hes1, a repressor
of NPC neuronal differentiation (Imayoshi et al., 2008; Kageyama
et al., 2008; Nakamura et al., 2000), and blocked the effect of
bradykinin in upregulating expression of Ngn2, a neurogenic
transcription factor. Additionally, p38 MAPK is involved in the
action of bradykinin in promoting migration during differentiation
(a schematic representation for the proposed mechanism of
bradykinin action is demonstrated in Fig. S4).
It is known that bradykinin stimulates proliferation in quiescent
cells, but suppresses it in cells under intense mitogenic stimulus
(Dixon et al., 2002; Duchene et al., 2002). Therefore, our findings
showing that bradykinin suppresses proliferation stimulated by
growth factors (FGF2 plus EGF) are in agreement with previous
studies. At the same time, it is known that growth factors maintain
multipotent NPCs by stimulating proliferative divisions, but these
cells remain subject to the influence of microenvironment,
especially during the G1 phase (Lukaszewicz et al., 2002;
Reynolds and Weiss, 1996). We observed that bradykinin leads to
an elongation of G1 phase and cell cycle. Thus, given that the
prolongation of G1 phase results in commitment to neuronal
differentiation by substituting proliferative divisions for neuron-
generating divisions (Calegari and Huttner, 2003; Lako et al., 2009;
Neganova et al., 2009), bradykinin could be fostering neurogenesis
by increasing G1-phase duration and thus removing NPCs from the
proliferative division induced by growth factors. We also observed
that bradykinin leads to neuron-generating division in vivo because
it increases expression of the TIS21 mRNA and Ki67 staining of
cells in hippocampal dentate gyrus. Thus, the apparent paradoxical
results of global proliferation in the in vitro and in vivo model of
bradykinin treatment can be explained because in the neurosphere
model, cells are proliferating whereas in the hippocampal dentate
gyrus they are in a quiescent state.
Many studies support the hypothesis that prolonged activation
kinetics, together with nuclear translocation of ERK, provide
specificity for this signal and constitute the dynamics of its
activation, which is necessary and sufficient to result in the
neurogenic response in PC12 cells and, possibly, in P19 cells
(Bouschet et al., 2003; Ebisuya et al., 2005; Reffas and Schlegel,
2000; Santos et al., 2007; Sasagawa et al., 2005; Traverse et al.,
1992). The present study is the first to investigate the kinetics and
sublocalization of ERK after stimulation with bradykinin in
undifferentiated neural cells (PC12 cells and NPCs), verifying a
mechanism of sustained activation and nuclear translocation similar
to that induced by neurogenic factors, such as NGF, PACAP and
retinoic acid (Marshall, 1995; Reffas and Schlegel, 2000; Vaudry
et al., 2002). Additionally, we investigated the involvement of ERK
in the differentiation of NPCs and PC12 cells. ERK inhibition
blocked the bradykinin effect in downregulating expression of
transcriptional repressor Hes1 and upregulating expression of
neurogenic transcription factor Ngn2. Moreover, we observed that
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both the direct inhibition of the MEK–ERK pathway with U0126
and PD98059 as well as the inhibition of one of its upstream
pathways (Gö6973; cPKC inhibitor), prevented neurogenesis
triggered by bradykinin. The inhibition of cPKC suggests the
importance of the specific dynamics of ERK activation induced
by bradykinin for neurogenic processes in PC12 cells. This
experimental approach disregards a possible influence of cPKC in
differentiation that is independent of the ERK pathway; however, it
was sufficient to propose the role of sustained ERK activation by
NGF in fostering differentiation (Santos et al., 2007). Considering
the effects of bradykinin on neurogenesis in NPCs and PC12 cells,
the dynamics of ERK activation is suggested to be implicated in the
mechanisms of bradykinin-induced neurogenesis.
MATERIALS AND METHODS
Culture of NPCs and PC12 cells
NPCs were isolated by dissection of embryo telencephalons (day 13.5) of
wild-type and B2BkR−/− C57BL/6 mice (provided by University of São
Paulo and Federal University of São Paulo). Mice were killed with
carbon dioxide. All animal experiments were carried out according to
protocols of the ethics committee (authorization number: 10/2013). Embryo
telencephalons were isolated and dissociated mechanically and by
enzymatic action of trypsin. 2×105 cells/ml were seeded in 2% (v/v) B-27
(Life Technologies, Carlsbad, CA), Dulbecco’s modified Eagle’s medium
(DMEM)with Ham’s F-12, 20 ng/ml EGF, 20 ng/ml FGF2 (Sigma-Aldrich,
St Louis, MO) and antibiotics. Neurospheres were seeded on poly-L-lysine-
and laminin-precoated plastic flasks and cultured in the presence of B-27 for
differentiation (Reynolds and Weiss, 1996; Trujillo et al., 2012).
PC12 rat pheochromocytoma cells ATCC No. CRL-1721 (Tischler and
Greene, 1975) were maintained in DMEM supplemented with 10% (v/v)
FBS, 5% horse serum (Life Technologies), glutamine and antibiotics. For
starvation conditions, cells were kept overnight in DMEM supplemented
with 1% horse serum. For induction of differentiation, PC12 cells were then
plated on adherent poly-L-lysine- and laminin-pre-coated cell culture grade
dishes for 2 days.
Cells were treated with U0126 (10 μM; Cell Signaling Technology,
Danvers, MA), PD98059 (20 μM; Sigma-Aldrich, St Louis, MO),
Ly294002 (20 μM; Tocris Bioscience, Bristol, UK), SB203580 (10 μM;
Cell Signaling Technology), PMA (1 μM; Tocris Bioscience), U73122
(10 μM; Sigma-Aldrich), Gö6973 (10 μM; Tocris Bioscience), YM254890
(10 μM; Astellas Pharma Ins., Miyukigaoka, Tsukuba, Japan), cholera toxin
(0.5 μM; Sigma-Aldrich), pertussis toxin (200 ng/ml; Sigma-Aldrich),
bradykinin (1 μM; Tocris Bioscience) and HOE-140 (1 μM; Tocris
Bioscience). It is known that B2BkR sequestration is rapid (half-life of
5 min) (Lamb et al., 2001; Munoz et al., 1993), but in view of possible
reappearance of accessible receptors, we added bradykinin into culture
medium every day during the migration and differentiation processes.
Intracellular cAMP and [Ca2+]i measurements
NPCs were untreated or pretreated and lysed directly in culture wells. Cyclic
AMP (cAMP) production was measured by the Amersham cAMP Biotrak
Enzymeimmunoassay (EIA) System (GE Healthcare, Waukesha, WI)
according to the manufacturer’s procedures.
For measurements of changes in intracellular free Ca2+ concentration
([Ca2+]i), NPCs were loaded with Fluo3-AM (5 µM) for 30 min at 37°C in
DMEM-F12 plus 0.5%Me2SO and 0.06% nonionic surfactant pluronic acid
F-127 (Sigma-Aldrich) (Martins et al., 2005). After 30 min of incubation
with Fluo-3AM, the cells were exposed to extracellular buffer and [Ca2+]i
imaging was immediately performed with an inverted research microscope
ECLIPSE-TiS (Nikon, Melville, NY) equipped with a 14-bit high-
resolution CCD camera CoolSNAP HQ2 (Photometrics, Tucson, AZ).
Fluorescence emission was recorded at 515–530 nm with image acquisition
rates of one frame per second; results were further analyzed with the NIS-
Element AR software (Nikon). Forty cells were analyzed for each data point
and [Ca2+]i levels were estimated by mean variation between Fluo-3AM
fluorescence intensities obtained upon stimulation with bradykinin (F) and
in the resting state (F0) divided by F0 (ΔF/F0).
Injection and immunohistochemistry
Prior to making an intracranial injection of the drugs, newborn pups (P0–P3)
were anesthetized by hypothermia, and mounted in stereotactic apparatus. 1
μl of the solution was injected using a 5 μl Hamilton syringe (32 gauge
needle) in two injection sites, 1 mm from the midline between the Bregma
and Lambda and 1–2 mm deep into the anterior lateral ventricles. The pups
were then placed on a heating pad for 3–5 min and returned to their mother
for further recovery. Mice (P7–P8) were deeply anesthetized with ketamine
and xylazine and their brains were carefully dissected. After 48 h of
incubation in 4% paraformaldehyde (PFA), brains were cryoprotected in
30% sucrose, and sectioned at a 40-µm thickness using a sledge microtome.
Free-floating sections of the entire hippocampus werewashed and incubated
for 2 h in a blocking solution (3% FBS, 0.1% Triton X-100 in PBS). Next,
sections were incubated overnight at 4°C with rabbit anti-DCX (1:500; cat.
no ab18723, Abcam, Cambridge, MA), rabbit anti-Ki-67 (1:1000; cat. no
ab15580, Abcam), chicken anti-MAP2 (1:2500; cat. no ab5392, Sigma-
Aldrich, St-Louis, MO) and mouse anti-NeuN (1:1000; cat. no MAB377,
Chemicon-Millipore, Billerica, MA) primary antibodies. After 24 h,
sections were washed and incubated for 2 h at room temperature with
secondary Alexa-Fluor-conjugated (1:1000; Life Technologies) antibodies.
Sections were washed, incubated with DAPI and mounted with DPX.
Images were obtained with a fluorescence microscope (Axiovert 200,
Zeiss), and analyzed with the Zen 2 software (Oberkochen, Germany) or
StrataQuest software (TissueGnostics GmbH, Vienna, Austria). Briefly, the
StrataQuest software is part of the TissueFAXS™ Cytometry platform – a
means of image cytometry of tissue sections, tissue- and cell-cultures with a
workflow and data display similar to flow cytometry. The software provides
cellular data in dot-plots to showmultiple measurement parameters of single
cells, multicellular structures and/or morphological features. Cut-off values
based on negative controls can be set to determine positive or negative
cell populations as observer-independent measurements. Gates are also
available to identify or work with cellular sub-populations.
Immunocytochemistry
Differentiated neurospheres were fixed in 4% PFA for 20 min and then
incubated for 20 min in PBS plus 3% FBS and 0.1% Triton X-100. After
that, cells were incubated with rabbit anti-GFAP (1:500; cat. no. Z0334,
DAKO Systems), rabbit anti-p-ERK (1:200; cat. no. 4370S, Cell Signaling
Technology), mouse anti-β3-tubulin (1:500; cat. no. T8660, Sigma-
Aldrich), rabbit anti-S100β (1:200; cat. no. G4546, Sigma-Aldrich), rabbit
anti-MAP2 (1:500; cat. no. 4542S, Cell Signaling Technology) or mouse
anti-Nestin (1:500; cat. no. MAB353, Millipore, Billerica, MA) antibodies
for 2 h. Sequentially, samples were washed twice and incubated at room
temperature with Alexa-Fluor-488-conjugated antibodies (1:1000; Life
Techologies) for 1 h. After that, cells were incubated with DAPI solution
(Sigma-Aldrich, 0.3 μg/ml) and mounted with DPX. Images were obtained
with a fluorescence microscope (Axiovert 200, Zeiss) (Trujillo et al., 2012).
Flow cytometry analysis of neural marker proteins and
phosphorylated proteins
Experiments for quantification of neural marker proteins were performed
according to Trujillo et al. (2012). Neurospheres were dissociated from the
flasks using trypsin and FBS. Single cells were washed with PBS, fixed for
20 min in ice-cold 4% PFA, washed with PBS 3% FBS, and incubated with
same antibodies described above in PBS plus 0.1% Triton X-100 and 3%
FBS for 30 min and, then, analyzed in a flow cytometer.
Flow cytometry experiments for measurement of phosphorylated proteins
were performed as previously described (Chow et al., 2001; Krutzik and
Nolan, 2003; Santos et al., 2007). Briefly, 6-h-starved NPCs were stimulated
and fixed for 10 min by adding 16% PFA directly into the culture medium to
obtain a final concentration of 4% of PFA. Cells were then permeabilized by
adding 90% ice-cold ethanol and incubated at 4°C for a least 10 min.
Primary staining was performed with monoclonal antibodies against the
phosphorylated proteins, rabbit anti-p-ERK (1:200; cat. no. 4370S, Cell
Signaling Technology), rabbit anti-p-Akt (1:100; cat. no. 2965S,
Cell Signaling Technology), rabbit anti-p-STAT3 (1:100; cat. no. 9145S,
Cell Signaling Technology), mouse anti-p-JNK (1:200; cat. no. 9255S, Cell
Signaling Technology) and anti-p-p38 (cat. no. 4511S 1:800; Cell Signaling
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Technology) followed by addition of secondary Alexa-Fluor-488-
conjugated antibodies (1:1000; Life Technologies). The measurements
were performed on an Attune Flow Cytometer (Life Technologies) and
analyzed with Flowjo V10 software (Flowjo, Ashland, OR).
BrdU incorporation assay for cell cycle and proliferation analysis
Cell proliferation and cell cycle were measured following incubation in
culture for 30 min or 2 h with 0.2 mM BrdU (Sigma-Aldrich) (Cappella
et al., 2008; Oliveira et al., 2013). Cells were fixed with ice-cold ethanol for
at least 4 h, incubated in 1.5 MHCl for 30 min and 0.1 M borate buffer (pH
8.0) for 5 min. Cells were then incubated with antibodies rat anti-BrdU
(1:200; cat. no. OBT0030, Accurate Chemical) or rabbit anti-Ki67 (1:500;
cat. no. AB9260, Chemicon-Millipore) antibodies. Some samples
(depending on the analysis) were incubated with propidium iodide
(50 μg/ml; Life Techologies) and RNAse A (50 μg/ml; Life Techologies)
for 20 min. Flow cytometry events were gated by FL2A versus FL2H for
doublet exclusion.
To better characterize the influence of bradykinin on proliferation, the
duration of cell cycle and its phases were examined by two methods with
flow cytometry experiments. With the first analysis (A), according to
Nowakowski et al. (1989) and Lukaszewicz et al. (2002), it is possible to
calculate the duration of the cell cycle, S-phase and the combined duration
of G1, G2 and M phases (G1+G2/M). These parameters were determined by
computing the labeling index values (BrdU treatment for 30 min and 2 h)
within the population of cycling cells (Ki67+; proliferation fraction). In the
second analysis (B), adapted from immunohistochemistry experiments of
Storey et al. (1989) and Wilcock et al. (2007), simultaneous equations were
used to calculate the duration of the cell cycle and S-phase. That is, (1)
length of S phase (denoted Ts)+[30 min (of treatment)−6 min]=percentage
of S-phase cells labeled in pulse×total time of cell cycle (denoted Tc) and (2)
Ts+(120 min−6 min)=percentage of S-phase cells labeled in pulse×Tc.
Furthermore, the length of the G2/M phase=percentage of cells in G2/M
phase (revealed by propidium iodide staining)×Tc. Finally, length of
G1 phase=Tc–Ts–time in G2 and M (denoted TG2/M) or length of G1
phase=time in G1, G2 and M phases (denoted TG1+G2/M)–TG2/M.
A minimum of 60,000 cells were analyzed per sample.
Extraction of nuclear and cytosolic fractions and western
blotting assays
Separation of nuclear and cytosolic fractions was performed with the NE-
PER®Nuclear and Cytoplasmic Extraction Reagents kit (Thermo Scientific,
Waltham, MA). Protein in sample buffer was separated by SDS-PAGE on a
10% polyacrylamide gel. Proteins were then transferred to a nitrocellulose
membrane (Thermo Scientific) in a wet system for 1 h at constant amperage
of 400 mA. The membranes were incubated with primary antibodies, such
as rabbit anti-p-ERK1/2 (1:1000, cat. no. 9101, Cell Signaling Technology),
mouse anti-ERK1/2 (1:1000, cat. no. SC-514302, Santa Cruz
Biotechnology, Dallas, TX), goat anti-Histone H1 (1:1000, sc 34464,
Santa Cruz Biotechnology) and mouse anti-β-actin (1:1000, cat. no. A5441,
Sigma-Aldrich) plus 1% BSA in Tris-buffered saline with 0.03% Tween-20
(TBS-T) overnight at 4°C. Membranes were probed with the respective
secondary antibodies for 1 h under agitation at room temperature.
Membranes were scanned with a laser scanner for biomolecular imaging
applications (Typhoon™, GE Healthcare). Detected bands were submitted
to densitometric analysis with the ImageJ software (National Institutes of
Health; this software can be obtained from http://imagej.net/Welcome).
Reverse transcription and quantitative polymerase chain
reaction
Total RNAwas obtained using the Trizol reagent (Life Technologies). After
DNAse I treatment, cDNAs were produced by SuperScript II Reverse
Transcriptase (Life Technologies). Specific mRNAs were analyzed by
SYBR Green real-time PCR on the ABI StepOnePlus Instrument (Life
Technologies). Primer sequences were: Hes1, forward primer 5′-TGCCT-
TTCTCATCCCCAACG-3′ and reverse primer 5′-AGGTGACACTGCG-
TTAGGAC-3′; GAPDH, forward primer 5′-TGCACCACCAACTGCTT-
AG-3′ and reverse primer 5′-GGATGCAGGGATGATGTTC-3′; TIS21,
forward primer 5′-ATGAGCCACGGGAAGAGAAC-3′ and reverse primer
5′-GCCCTACTGAAAACCTTGAGTC-3′; Mash1, forward primer 5′-GCC-
TCCAATTGAAGCAACGTC-3′ and reverse primer 5′-AGAAGCAAAGA-
CCGTGGGAG-3′; Ngn2, forward primer 5′-TCGGCTTTAACTGGA-
GTGCC-3′ and reverse primer 5′-GTGTGTTGTCGTTCTCGTGC-3′.
Thermal cycling conditions consisted of 50°C for 2 min, 95°C for 10 min,
and 50 cycles of 95°C for 15 s and 60°C for 1 min. The 2−ΔΔCt parameter
was used for quantification and GAPDH gene expression was used as
internal standard (Lameu et al., 2012; Livak and Schmittgen, 2001).
Statistical analysis
The results are expressed as mean±s.e.m. from three or more independent
experiments. Statistical comparisons between different treatments, with
normal distribution, were performed by either a Student’s t-test and/or
two-way analysis of variance (ANOVA) with a Bonferroni post hoc test by
using GraphPad Prism 5.1 software (La Jolla, CA). The criteria for statistical
significance were set at P<0.05. For flow cytometry, a minimum of 30,000
cells was analyzed per sample. A minimum of 300 and up to 800 cells per
sample was counted for quantification of immunolabeled cells or cells
captured by differential interference contrast (DIC) microscopy.
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